Resumen de Updated management of Gout

Cristian Javier Calle Cárdenas, Myriam Lizeth Morales Pilataxi, María Victoria Silva Ramos

• The research addresses updates in the management of gout, one of the most common inflammatory arthritis that affects approximately 4% of adults in the United States and is prevalent worldwide, especially in men. Despite biological knowledge about the relationship between hyperuricemia and gout, only about one-third of patients receive uricemia-lowering therapy (ULT). The problem lies in the underdiagnosis and poor treatment of the disease. The 2020 guideline emphasizes the use of stable, urine-lowering therapy, an approach based on serial measurements of serum urate to adjust doses and maintaining an SU target of 6.0 mg/dL indefinitely. The evolution is evident in the recommendations on asymptomatic hyperuricemia, now addressed conditionally according to the presence of subcutaneous tophi, radiographic damage and other factors.